Using liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based metabolomics, our recent research identified sEH, a downstream enzyme involved in the CYP monooxygenase eicosanoid pathway [2], as a novel therapeutic target of obesity-induced colonic inflammation [41]. The gene discussed is EPHX2; the disease is obesity disorder.